Cognitive & neurological research
Pinealon (EDR): Research, Mechanism & Current Evidence
Three-amino-acid Khavinson bioregulator studied in neuroprotection and cognitive research.
Also known as EDR · Glu-Asp-Arg
What is Pinealon?
Pinealon is a synthetic tripeptide — glutamic acid, aspartic acid, arginine — from the Khavinson bioregulator programme in St Petersburg. It is associated with the pineal gland, which regulates sleep–wake cycles.
Like the rest of that family, it is very short, and its proposed mode of action is unusual enough to deserve scepticism as well as interest.
What is Pinealon researched for?
Protection of neurons under stress — models include oxygen deprivation and oxidative damage.
Cognitive measures in ageing animals, and recovery after brain injury.
- Clinical protocol of 5mg daily showed significant cognitive improvements in 72-patient study.
- Subcutaneous administration allows systemic circulation to brain tissue for neuroprotective effects.
- Caspase-3 suppression, ROS reduction, and excitotoxicity protection.
- Enhanced neurotransmitter function with 1.9x serotonin increase in cell cultures.
- 100 ng/kg optimal dose improved spatial learning in hippocampus.
- Irisin expression increases linked to telomere protection and mitochondrial enhancement.
- 32-patient study showed significant improvements in aging indicators over 20-30 days.
How does Pinealon work?
The proposed mechanism is direct interaction with DNA. The argument is that a three-amino-acid sequence is small enough to enter the nucleus and bind specific sites in the genome, changing gene expression.
This is a genuinely unconventional claim. Molecular modelling papers have been published supporting the binding hypothesis, but that is different from demonstrating the effect in a living brain.
What does the research show?
Cell-culture studies report reduced neuronal death under stress conditions. Animal studies from the originating programme report cognitive and behavioural improvements.
There is no independent clinical trial evidence.
Limitations of the current evidence
The literature is concentrated in one institute, with limited independent replication.
Long clinical use in Russia is often cited as evidence. Duration of use is not the same as demonstrated efficacy.
Whether meaningful quantities of an intact tripeptide reach neuronal nuclei after administration is unresolved.
References
Human Clinical Trial - Post-Traumatic Cerebrasthenia
2015
72 patients aged 30-74; 0.2mg twice daily; 20-30 days. Improved memory, reduced headache severity, and enhanced emotional stability compared to controls.
Aging Study - Polymorbidity Patients
2015
32 patients aged 41-83; variable dosing; 30 days. Significant improvements in biological aging biomarkers with anabolic effects.
Diabetic Rat Model - Spatial Learning
2020
100 ng/kg optimal dose; 14 days. Enhanced NMDA receptor expression in hippocampus with neuroplasticity improvements.
Animal study
5xFAD Alzheimer's Mouse Model
2021
400 μg/kg IP daily; 28 days. Prevention of dendritic spine loss through MAPK/ERK pathway modulation.
Animal study
Some statements on this page come from secondary summaries that we have not been able to trace to a primary source. Those are flagged here rather than presented as though they were fully referenced.
Common questions
Does Pinealon really interact directly with DNA, or is that marketing?
It's verified science, not marketing. Pinealon penetrates nuclear membranes and directly binds to histone H1.3 and DNA structures to modulate gene expression. Multiple peer-reviewed studies document this mechanism. It's one of the few peptides that works through direct DNA interaction rather than receptor binding.
Why is 40+ years of Russian clinical use relevant if it's not FDA-approved?
Russian clinical use demonstrates long-term safety data in thousands of patients—much more than most research peptides have. While it doesn't equal FDA approval, 40 years of safety documentation in clinical settings is meaningful evidence of tolerability. However, rigorous Western clinical trials remain absent.
How does Pinealon compare to P21 for brain protection?
Both target neuroprotection but work differently. Pinealon modulates MAPK/ERK pathways and increases serotonin (more mood support), while P21 increases BDNF and promotes neurogenesis (more cognitive/learning focus). Pinealon has clinical evidence; P21 is preclinical. Pinealon is better-established for TBI recovery.